Literature DB >> 21867613

[Cyclin D1, hTERT expression and telomerase activity in HL-60 and HL-60A cell lines and their significance].

Ke-Zhi Huang1, Da-Nian Nie, Song-Mei Yin, Yi-Qing Li, Shuang-Feng Xie, Li-Ping Ma, Xiu-Ju Wang, Yu-Dan Wu.   

Abstract

To observe the expression of cyclin D1, hTERT, and telomerase activity in MNC, HL-60, HL-60A and to explore their effects on leukemogenesis and drug-resistance, normal human peripheral blood mononuclear cells, HL-60 cells sensitive to adriamycin and HL-60A cells resistant to adriamycin were investigated. The cell cycle was analyzed by flow cytometry, and the apoptosis was analyzed by Annexin V-FITC(+) PI staining. Expressions of cyclin D1 and hTERT were determined by real-time PCR and Western blot. Telomerase activity was detected by TRAP-ELISA. The results indicated that the percentage of MNC, HL-60 and HL-60A in S phase was (10.21 + 2.11)%, (44.93 + 3.00)%, and (51.38 + 1.10)% respectively; the percentage of apoptosis cells was (16.14 + 2.13)%, (7.53 + 0.92)%, (4.15 + 0.96)% respectively; the expression of mRNA and protein for cyclin D1 and hTERT increased; the telomerase activities of HL-60 and HL-60A were higher (p = 0.000), whereas the difference between HL-60 and HL-60A was no statistically significant (p = 0.232); positive correlation between cyclin D1, hTERT and telomerase activity had been found (p < 0.01). It is concluded that the cells of S phase increased while the apoptotic cells decreased in HL-60 and HL-60A, especially in HL-60A, which may be due to the up-regulation of cyclin D1, hTERT and telomerase activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21867613

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

1.  Ginger extract adjuvant to doxorubicin in mammary carcinoma: study of some molecular mechanisms.

Authors:  Nahla E El-Ashmawy; Naglaa F Khedr; Hoda A El-Bahrawy; Hend E Abo Mansour
Journal:  Eur J Nutr       Date:  2017-02-22       Impact factor: 5.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.